Antisense Therapeutics Limited Stock Market Capitalization
Antisense Therapeutics Limited fundamentals help investors to digest information that contributes to Antisense Therapeutics' financial success or failures. It also enables traders to predict the movement of Antisense Pink Sheet. The fundamental analysis module provides a way to measure Antisense Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Antisense Therapeutics pink sheet.
Antisense |
Antisense Therapeutics Limited Company Market Capitalization Analysis
Antisense Therapeutics' Market Capitalization is the total market value of a company's equity. It is one of many ways to value a company and is calculated by multiplying the price of the stock by the number of shares issued. If a firm has one type of stock its market capitalization will be the current market share price multiplied by the number of shares. However, if a company has multiple types of equities then the market cap will be the total of the market caps of the different types of shares.
Current Antisense Therapeutics Market Capitalization | 41.78 M |
Most of Antisense Therapeutics' fundamental indicators, such as Market Capitalization, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Antisense Therapeutics Limited is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In most publications or references market cap is broken down into the mega-cap, large-cap, mid-cap, small-cap, micro-cap, and nano-cap. Market Cap is a measurement of business as total market value of all of the outstanding shares at a given time, and can be used to compare different companies based on their size.
CompetitionBased on the recorded statements, the market capitalization of Antisense Therapeutics Limited is about 41.78 M. This is 99.68% lower than that of the Healthcare sector and significantly higher than that of the Drug Manufacturers—Specialty & Generic industry. The market capitalization for all United States stocks is 99.78% higher than that of the company.
Antisense Market Capitalization Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Antisense Therapeutics' direct or indirect competition against its Market Capitalization to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Antisense Therapeutics could also be used in its relative valuation, which is a method of valuing Antisense Therapeutics by comparing valuation metrics of similar companies.Antisense Therapeutics is currently under evaluation in market capitalization category among its peers.
Antisense Fundamentals
| Return On Equity | -0.43 | |||
| Return On Asset | -0.25 | |||
| Operating Margin | (3.28) % | |||
| Current Valuation | 27.82 M | |||
| Shares Outstanding | 669.04 M | |||
| Shares Owned By Insiders | 19.30 % | |||
| Shares Owned By Institutions | 4.93 % | |||
| Price To Earning | (3.62) X | |||
| Price To Book | 3.05 X | |||
| Price To Sales | 24.46 X | |||
| Revenue | 1.78 M | |||
| Gross Profit | 1.71 M | |||
| EBITDA | (7.52 M) | |||
| Net Income | (5.81 M) | |||
| Cash And Equivalents | 19.23 M | |||
| Cash Per Share | 0.03 X | |||
| Total Debt | 227.4 K | |||
| Debt To Equity | 0.01 % | |||
| Current Ratio | 19.14 X | |||
| Book Value Per Share | 0.03 X | |||
| Cash Flow From Operations | (7.81 M) | |||
| Earnings Per Share | (0.01) X | |||
| Number Of Employees | 12 | |||
| Beta | 0.67 | |||
| Market Capitalization | 41.78 M | |||
| Total Asset | 22.44 M | |||
| Retained Earnings | (53 M) | |||
| Working Capital | 4 M | |||
| Current Asset | 5 M | |||
| Current Liabilities | 1000 K | |||
| Net Asset | 22.44 M |
Currently Active Assets on Macroaxis
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in inflation. You can also try the Content Syndication module to quickly integrate customizable finance content to your own investment portal.
Other Consideration for investing in Antisense Pink Sheet
If you are still planning to invest in Antisense Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Antisense Therapeutics' history and understand the potential risks before investing.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges |